YG1699

YG1699 is an orally administered, small molecule drug candidate developed by Youngene Therapeutics. It acts as a dual inhibitor of sodium-glucose transporter 1 (SGLT1) and sodium-glucose transporter 2 (SGLT2), with high potency for both targets. By inhibiting SGLT1 in the gastrointestinal tract and SGLT2 in the kidneys, YG1699 reduces glucose absorption from the intestine and increases urinary glucose excretion, leading to improved glycemic control. Preclinical studies have shown that it suppresses plasma glucose increases after oral glucose challenges and elevates incretin hormones such as GLP-1 and PYY. In clinical trials, YG1699 has demonstrated dose-dependent reductions in postprandial blood glucose levels and was well tolerated with a favorable safety profile. The drug is being developed primarily for type 1 diabetes mellitus but is also under investigation for type 2 diabetes mellitus, diabetic nephropathies (including chronic kidney disease associated with diabetes), heart failure, and cystic fibrosis[1][2][3][4][5][6].